Low inspiratory capacity to total lung capacity ratio is a risk factor for chronic obstructive pulmonary disease exacerbation

American Journal of the Medical Sciences

Volumn 339, Issue 5, 2010, Pages 411-414

  Zaman, Mumtaz ^a   Mahmood, Syed ^a   Altayeh, Abdullah ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

COPD; Exacerbation; Hyperinflation; IC TLC ratio

Indexed keywords

ADULT; AGED; AIRFLOW; AMBULATORY CARE; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; EMERGENCY WARD; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; RESIDUAL VOLUME; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TOTAL LUNG CAPACITY;

EID: 77952282161     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181d6578c     Document Type: Article

References (36)

1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80.
2. O'Donnell DE, Bertley JC, Chau LK, et al. Qualitative aspects of exertional breathlessness in chronic airflow limitation. Am J Respir Crit Care Med 1997;155:109-15.
3. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:770-7.
4. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:591-7.
5. Katsura H, Ogata M, Kida K. Factors determining outcome in elderly patients with severe COPD on long-term domiciliary oxygen therapy. Monaldi Arch Chest Dis 2001;56:195-201.
6. Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen therapy reduce hospitalization in hypoxaemic chronic obstructive pulmonary disease. Eur Repir J 2002;20:38-42.
7. Eaton T, Lewis C, Young P, et al. Long-term oxygen therapy improves health-related quality of life. Respir Med 2004; 98; 285-93.
8. Haidl P, Clement C, Wiese C, et al. Long-term oxygen therapy stops the natural decline of endurance in COPD patients with reversible hypercapnia. Respiration 2004;71:342-7.
9. Vitacca M. Exacerbations of COPD: predictive factors, treatment, and outcome. Monaldi Arch Chest Dis 2001;56:137-43.
10. Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005;26:234-41.
11. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154:959-67.
12. Garcia-Rio F, Lores V, Mediano O, et al. Daily physical activity in patients with COPD is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med 2009;180:506-12.
13. Duranti R, Filippelli M, Biachi R, et al. Inspiratory Capacity and Decrease in Lung Hyperinflation with Albuterol in COPD. Chest 2002;122:2009-14.
14. Di Marco F, Milic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003;21:86-94.
15. Celli B, Zuwallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;124:1743-8.
16. Roche N. Mode of action of bronchodilators in COPD. Aims of their use and criteria of assessment [in French]. Presse Med 2004;33:104-10.
17. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40.
18. Manriquez J, Diaz O, Borzone G, et al. Spirometric reversibility to salbutamol in chronic obstructive pulmonary disease (COPD). Differential effects on FEV1 and on lung volumes [in Spanish]. Rev Med Chil 2001;132:787-93.
19. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
20. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
21. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007;131:696-704.
22. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
23. Centers for Disease Control and Prevention (CDC). State-specific prevalence and trends in adult cigarette smoking-United States, 1998-2007. MMWR Morb Mortal Wkly Rep 2009;58:221-6.
24. Prescott E, Bjerg AM, Anderson PK, et al. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 1997;10:822-7.
25. De Torres JP, Casanova C, Hernandez C, et al. Gender and COPD in patients attending a pulmonary clinic. Chest 2005;128:2012-6.
26. Somfay A, Porszasz J, Lee SM, et al. Effect of hyperoxia on gas exchange and lactate kinetics following exercise onset in nonhypoxemic COPD patients. Chest 2002;121:393-400.
27. Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodeling in smokers and patients with mild COPD. Eur Respir J 2002;19:632-8.
28. Debigare R, Maltais F. The major limitation to exercise performance in COPD is lower limb muscle dysfunction. J Appl Physiol 2008;105:751-3; discussion 755-7.
29. Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005;25:186-99.
30. Vogiatzis I, Georgiadou O, Golemati S, et al. Patterns of dynamic hyperinflation during exercise and recovery in patients with severe chronic obstructive pulmonary disease. Thorax 2005;60:723-9.
31. Aliverti A, Rodger K, Dellaca RL, et al. Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD. Thorax 2005;60:916-24.
32. Casaburi R, Conoscenti CS. Lung function improvements with oncedaily tiotropium in chronic obstructive pulmonary disease. Am J Med 2004; 117 (suppl 12A) : 33S-40S.
33. Marinez FJ, de Oca MM, Whyte RI, et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997;155:1984-90.
34. Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791-7.
35. Prescott E, Almdal T, Mikkelsen KL, et al. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur Respir J 2002;20:539-44.
36. Marin JM, Carrizo SJ, Gascon M, et al. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1395-9.